Nasdaq · CIK 0001778016
NBP NovaBridge Biosciences
Insider trading from SEC Form 4. Last filing 22 d ago. Close $1.39 on Oct 9, 2026, +4% from the 52-week low and -79% from the high.
NovaBridge Biosciences (NBP) has 7 SEC Form 4 filings on file from 3 insiders, the latest filed on Sep 21, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 3 open-market sells worth $88k, net -$88k.
5 open-market trades have been scored at NBP. The newest: Phillip Andrew Dennis (Chief Medical Officer) sold $5,828 of stock on Sep 18, 2026, filed Sep 21, 2026, scored 8 (weak). The largest of the 5 shown: Sean Wuxiong Cao (Chief Bus. Development Officer) sold $80k on Sep 9, 2026, scored 49 (moderate). 2 insiders sold within 14 days of each other around Sep 18, 2026.
NBP closed at $1.39 on Oct 9, 2026, 4% above its 52-week low and 79% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at NovaBridge Biosciences, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 8Weak | Phillip Andrew Dennis Chief Medical Officer sell | $5,828 8,209 shares | -5% | - | |
| 49Moderate | Sean Wuxiong Cao Chief Bus. Development Officer sell | $80k 107,978 shares | -29% | - | |
| 8Weak | Cong Claire Xu EVP, Clinical Development sell | $2,593 3,282 shares | -1% | - | |
| 0Weak | Phillip Andrew Dennis Chief Medical Officer sell | $5,606 8,494 shares | -5% | +2% from low-77% from high | |
| 31Weak | Sean Wuxiong Cao See Remarks sell | $43k 21,399 shares | -38% | +118% from low-71% from high |
Transactions
Every row filed, 17 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Phillip Andrew Dennis Chief Medical Officer | MOption exercise Ordinary Shares | +23,695 | - | - | 181,636 | 22 d ago |
| Sep 18, 2026 | Phillip Andrew Dennis Chief Medical Officer | SOpen-market sale Ordinary Shares | -8,209 | $0.71 | $5,828 | 173,427 | 22 d ago |
| Sep 17, 2026 | Phillip Andrew Dennis Chief Medical Officer | MOption exercise Restricted Share Unitsderivative | -10,302 | $0.00 | $0 | 72,120 | 22 d ago |
| Sep 9, 2026 | Sean Wuxiong Cao Chief Bus. Development Officer | SOpen-market sale Ordinary Shares | -107,978 | $0.74 | $80k | 266,467 | 32 d ago |
| Sep 3, 2026 | Sean Wuxiong Cao Chief Bus. Development Officer | MOption exercise Ordinary Shares | +235,136 | - | - | 270,209 | 35 d ago |
| Sep 3, 2026 | Sean Wuxiong Cao Chief Bus. Development Officer | MOption exercise Ordinary Shares | +104,236 | - | - | 374,445 | 35 d ago |
| Sep 3, 2026 | Sean Wuxiong Cao Chief Bus. Development Officer | MOption exercise Restricted Share Unitsderivative | -102,233 | $0.00 | $0 | 306,700 | 35 d ago |
| Sep 3, 2026 | Sean Wuxiong Cao Chief Bus. Development Officer | MOption exercise Restricted Share Unitsderivative | -45,320 | $0.00 | $0 | 135,960 | 35 d ago |
| Aug 30, 2026 | Cong Claire Xu EVP, Clinical Development | MOption exercise Ordinary Shares | +9,382 | - | - | 307,483 | 42 d ago |
| Aug 31, 2026 | Cong Claire Xu EVP, Clinical Development | SOpen-market sale Ordinary Shares | -3,282 | $0.79 | $2,593 | 304,201 | 42 d ago |
| Aug 30, 2026 | Cong Claire Xu EVP, Clinical Development | MOption exercise Restricted Share Unitsderivative | -4,079 | $0.00 | $0 | 28,558 | 42 d ago |
| Jun 22, 2026 | Sean Wuxiong Cao Chief Bus. Development Officer | AGrant or award Restricted Share Unitsderivative | +181,280 | $0.00 | $0 | 181,280 | Jun 24, 2026 |
| Jun 22, 2026 | Sean Wuxiong Cao Chief Bus. Development Officer | AGrant or award 2025 Employee Share Option (right to buy)derivative | +181,290 | $0.00 | $0 | 181,290 | Jun 24, 2026 |
| Jun 17, 2026 | Phillip Andrew Dennis Chief Medical Officer | MOption exercise Ordinary Shares | +23,695 | - | - | 166,435 | Jun 22, 2026 |
| Jun 18, 2026 | Phillip Andrew Dennis Chief Medical Officer | SOpen-market sale Ordinary Shares | -8,494 | $0.66 | $5,606 | 157,941 | Jun 22, 2026 |
| Jun 17, 2026 | Phillip Andrew Dennis Chief Medical Officer | MOption exercise Restricted Share Unitsderivative | -10,302 | $0.00 | $0 | 82,422 | Jun 22, 2026 |
| May 14, 2026 | Sean Wuxiong Cao See Remarks | SOpen-market sale Ordinary Shares | -21,399 | $1.99 | $43k | 35,073 | May 18, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Sean Wuxiong CaoChief Bus. Development Officer
- Phillip Andrew DennisChief Medical Officer
- Cong Claire XuEVP, Clinical Development
Questions about NBP
Answered from the filings on this page, as of the latest one.
Are insiders buying NBP?
As of Sep 21, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 3 open-market sells worth $88k by 3 insiders at NovaBridge Biosciences in the last 90 days, net -$88k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade NBP on the open market?
Phillip Andrew Dennis (Chief Medical Officer) sold $5,828 of NBP on Sep 18, 2026 and filed the Form 4 on Sep 21, 2026. InsiderTell scored 8 (weak), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at NovaBridge Biosciences?
3 people have filed a Form 4 at NovaBridge Biosciences, among them Sean Wuxiong Cao (Chief Bus. Development Officer), Phillip Andrew Dennis (Chief Medical Officer), Cong Claire Xu (EVP, Clinical Development). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.